Radiation therapy for small kidney tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of kidney cancer (clear cell type or similar).
- Your tumor is 7 cm or smaller and has not spread to other parts of the body.
- You are not a candidate for surgery due to medical reasons or you choose not to have surgery.
- Your kidney function is good (eGFR is 30 or higher).
- You have not had radiation to the same area or systemic therapy for kidney cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a precise form of radiation therapy called stereotactic body radiotherapy (SBRT) that tracks the tumor during treatment to destroy kidney tumors without surgery. It may be an option if you have a kidney tumor (primary or spread from another cancer) up to 10 cm in size and you haven't had radiation to that area before.
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests a precise type of radiation called stereotactic body proton therapy for people with kidney cancer who cannot have surgery or other local treatments. It aims to see if this focused radiation can control the tumor with fewer side effects.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.